MARKET

GNPX

GNPX

Genprex Inc
NASDAQ
2.070
+0.070
+3.50%
After Hours: 2.101 +0.031 +1.48% 19:45 03/04 EST
OPEN
2.060
PREV CLOSE
2.000
HIGH
2.140
LOW
1.970
VOLUME
451.25K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
1.710
MARKET CAP
4.80M
P/E (TTM)
-0.0392
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GNPX last week (0223-0227)?
Weekly Report · 3d ago
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying
Benzinga · 02/25 23:20
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 02/23 17:05
Genprex Secures Key Global Patents for REQORSA Therapy
TipRanks · 02/23 13:51
Genprex granted Japanese and EU patents for Reqorsa Gene Therapy
TipRanks · 02/23 13:12
Genprex Says Japanese Patent Office Issues Favourable Appeal Decision To Grant Patent Claiming Use Of Reqorsa Gene Therapy In Combination With PD-L1 Antibodies To Treat Cancer
Benzinga · 02/23 13:09
Genprex Wins Japanese and European Patent Grants for Reqorsa Gene Therapy Combinations With PD-1/PD-L1 Immunotherapies
Reuters · 02/23 13:01
Weekly Report: what happened at GNPX last week (0216-0220)?
Weekly Report · 02/23 10:13
More
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Webull offers Genprex Inc stock information, including NASDAQ: GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.